PCR Journal Club

This study challenges the double-jeopardy assumption as the main cause of adverse outcome in STEMI with non-IRA CTO, as a collateral origin distal from the acute IRA occlusion was associated with a significantly better prognosis than with a proximal origin.

The present study showed that compared to clopidogrel, ticagrelor and prasugrel have comparable 1-year efficacy and safety profiles in individuals with CCS undergoing PCI. 

This pilot study aimed to investigate the feasibility, safety, and efficacy (long-term patency) of the recanalization of chronic RAO via DRA7.

FAVOR-III China was an investigator-initiated, multicentre, randomised, blinded, sham-controlled trial comparing clinical outcomes of QFR versus angiography-guided strategies for the treatment of non-critical lesions in patients with stable or unstable angina, or MI, at least 72 hours prior to screening. The one-year results showed improved clinical...

The HOST-EXAM trial1 was a prospective, randomised, open-label trial investigating clopidogrel monotherapy versus aspirin therapy in patients undergoing PCI with DES who had completed 6-18 months of DAPT with no ischaemic or bleeding complications. At 24 months follow-up, clopidogrel monotherapy significantly reduced the risk of the...

This sub-analysis of ISCHEMIA has shown that implementation of a simple protocol of optimal medical therapy is a key factor to improve health outcome and practical in real-world settings.

In this post-hoc analysis of the TWILIGHT trial, the authors report the effects of ticagrelor monotherapy compared to ticagrelor and aspirin in patients with prior CABG at least three months post PCI with no adverse events and at least one clinical and one angiographic high-risk feature...

The primary objective of the study was to assess whether an IVUS-based stent optimization provided an incremental value in terms of vessel-related adverse event occurrence in patients presenting with low post-PCI FFR (<0.90).

The STRENGTH study is a multicentre prospective randomised trial investigating whether RenalGuard is superior to standard intravenous hydration in preventing contrast induced nephropathy in patients with chronic kidney disease (CKD) undergoing complex cardiovascular procedures.

This analysis of the large multinational Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS‐CTO) registry1 examined prevalence, temporal trends, and clinical outcomes of radial versus femoral access in CTO PCI.